Trending News – July 22, 2021

In this minisode, Mindy, Ryan, and Jen discuss a few recent newsworthy items including: the Biden administration’s interim final rule banning surprise billing (00:35), Walmart’s launch of a private band insulin analog (04:21), and interim trial results for in vivo CRISPR-based genome editing candidate NTLA-2001 (07:00).

Podcast Tags: surprise billing, health insurance, diabetes, drug prices, gene therapy, CRISPR, healthcare, healthcare news

Source Links:

· https://www.fiercehealthcare.com/payer/biden-admin-releases-first-interim-final-rule-to-ban-surprise-medical-bills-sets?mkt_tok=ODUwLVRBQS01MTEAAAF-ELDJl4M5DBFZ7_MJTdaVw2W_WtZeiSWcn

· https://www.beckershospitalreview.com/finance/cms-unveils-surprise-billing-rule-10-things-to-know.html

· https://www.fiercehealthcare.com/finance/walmart-teams-novo-nordisk-to-launch-private-band-analog-insulin?utm_medium=nl&utm_source=internal&mrkid=65631392&mkt_tok=Mjk0LU1RRi0wNTYAAAF9_AB9bhrYERn_F0_Z_CFgnxi3JFoDbFYYjLV3ub090Lsk6j0dRKGECO_qGldwPtxlXqbfHOT4W09v3LzWGRKpmSFxz_j8dNYwt3sqlB5Nr4esKYBRlg

· https://www.statnews.com/pharmalot/2021/06/29/walmart-insulin-novo-nordisk-diabetes/?mkt_tok=ODUwLVRBQS01MTEAAAF9-91CzqJAe-LL33Gy4FjrwKJDFCfhES48aNg7kB7S_naKvfyJrEjqeHn8s6J5z34wAaGJdW4uvctwaadx9b64EBOjreZh8VfoIbEaDj06GnUa

· https://www.fiercebiotech.com/biotech/first-human-trial-results-intellia-shows-world-gene-editing-has-arrived?mkt_tok=Mjk0LU1RRi0wNTYAAAF-BlNHkt2Maf8F2j4tTY34Nbfr768q_-NEJlovuUC8YR5R6kmRnizLOIUHMuBx4yD_H3cwxx1YhNslaO10Zfx505MYvFxg2Zd5w8yFVCJGLpWlyzkEjg&mrkid=65631392

· https://www.statnews.com/2021/06/26/intellia-therapeutics-ntla-2001-data/?utm_source=STATNewsletters&utm_campaign=63bbc01b83-MR_COPY_14&utm_medium=email&utm_term=0_8cab1d7961-63bbc01b83-149847573

For additional discussion, please contact us at TrendingHealth.com or share a voicemail at 1-888-VYNAMIC.

Mindy McGrath, Healthcare Industry Learning Lead

[email protected]

Ryan Hummel, Executive and Head of Provider Sector

[email protected]

Jen Burke, Healthcare Industry Strategist

[email protected]